Cytosorbents Corp
CTSO- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001175151
In the last 90 days, Cytosorbents Corp insiders filed 4 open-market purchases and 0 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $6.04M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $18.2M
- Insider buysLast 90 days, $120.4K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 50
- 13F valueReported value at the end of Q2 2026
- $6.04M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $37.1M
- +4.1% year over year
- Net income, FY2025
- -$8.20M
- No comparable prior period
- Free cash flow, FY2025
- -$12.5M
- No comparable prior period
- Revenue, Q2 FY2026
- $9.63M
- +0.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $8.20M (22.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 114.4K
- Shares sold short
- Change
- −9.49K
- −7.7% vs. previous
- Days to cover
- 10.27
- At average daily volume
Superinvestors holding CTSO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CTSO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cytosorbents Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)5:30 PM ET | Sep 15 | 1 day | Chan Phillip P.Chief Executive Officer | PPurchase | +3.77K | $6.00 | +$22.6K | +3.9%101.0K after | |
| Sep 16, 2026 (view filing)4:05 PM ET | Sep 14 | 2 days | Capponi VincentPresident and COO | PPurchase | +2.07K | $6.05 | +$12.5K | +5.4%40.4K after | 2 lots |
| Sep 16, 2026 (view filing)4:05 PM ET | Sep 15 | 1 day | Sobel Alan D.Director | PPurchase | +2.50K | $6.10 | +$15.3K | +33.8%9.89K after | 3 lots |
| Sep 9, 2026 (view filing)4:05 PM ET | Sep 4 | 5 days | Chan Phillip P.Chief Executive Officer | PPurchase | +200.0K | $0.35 | +$70.0K | +11.5%1.94M after | |
| Jun 16, 2026 (view filing)7:00 AM ET | Jun 15 | 1 day | Mariani Peter JChief Financial Officer | PPurchase | +100.0K | $0.44 | +$44.0K | +18.6%638.1K after | |
| Jun 15, 2026 (view filing)6:24 PM ET | Jun 12-15 | 3 days | Chan Phillip P.Chief Executive Officer | PPurchase | +261.5K | $0.4012 | +$104.9K | +17.6%1.74M after | 2 lots |
| Dec 16, 2024 (view filing) | Dec 13 | 3 days | Mariani Peter JChief Financial Officer | PPurchase | +20.0K | $0.96 | +$19.2K | +5.2%401.4K after | |
| Dec 13, 2024 (view filing) | Dec 11-12 | 2 days | Mariani Peter JChief Financial Officer | PPurchase | +31.4K | $0.89 | +$27.9K | +9.0%381.4K after | 2 lots |
| Dec 15, 2023 (view filing) | Dec 13 | 2 days | Sobel Alan D.Director | PPurchase | +22.6K | $1.33 | +$30.0K | +28.4%101.9K after | |
| Dec 15, 2023 (view filing) | Dec 13 | 2 days | Sobel Alan D.Director | PPurchase | +7.89K | – | – | –7.89K after | Derivative |
Top 10 13F holders, Q2 2026
See all 50 holdersThe largest institutional positions in Cytosorbents Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Avenir Corp | 5,189,218 | $1.94M | 0.24% | −26,558−0.5% | Reduced |
| Neuberger Berman Group LLC | 1,968,691 | $740.5K | 0.00% | +285,684+17.0% | Added |
| Vanguard Capital Management LLC | 1,914,063 | $715.9K | 0.00% | +34,074+1.8% | Added |
| CM Management, LLC | 1,476,500 | $552.2K | 0.35% | 00.0% | Unchanged |
| Skylands Capital, LLC | 1,211,400 | $453.1K | 0.06% | −496,098−29.1% | Reduced |
| BlackRock, Inc. | 627,211 | $234.6K | 0.00% | −155,781−19.9% | Reduced |
| Geode Capital Management, LLC | 602,059 | $225.2K | 0.00% | −105,203−14.9% | Reduced |
| Sargent Investment Group, LLC | 555,757 | $207.9K | 0.02% | +5,857+1.1% | Added |
| Pathstone Holdings, LLC | 499,910 | $187.0K | 0.00% | −450.0% | Reduced |
| Vanguard Fiduciary Trust Co | 316,167 | $118.2K | 0.00% | +2,311+0.7% | Added |
Holders of 5% or more of CTSO
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cytosorbents Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avenir Corp | 13G/A | 8.30%5.23M shares | +2.60 ppfrom 5.70% | Dec 13, 20219 filings | Feb 13, 2026 | SEC |
| Satterfield Thomas A Jr | 13G | 6.56%4.00M shares | New | Jan 17, 20251 filing | Jan 17, 2025 | SEC |
| Avenue Venture Opportunities Fund, L.P. | 13G | 5.70%3.76M shares | New | May 28, 20251 filing | May 28, 2025 | SEC |